Holen Sie sich die Stockscreener-App
37.25
2.99%
1.08
Schlusskurs vom Vortag:
$36.17
Offen:
$36.37
24-Stunden-Volumen:
749.41K
Relative Volume:
0.68
Marktkapitalisierung:
$4.22B
Einnahmen:
$14.09M
Nettoeinkommen (Verlust:
$-176.94M
KGV:
-17.33
EPS:
-2.15
Netto-Cashflow:
$-141.24M
1W Leistung:
+5.64%
1M Leistung:
-2.77%
6M Leistung:
+77.13%
1J Leistung:
+48.47%
1-Tages-Spanne:
$35.75
$37.25
1-Wochen-Bereich:
$34.59
$37.25
52-Wochen-Spanne:
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Vergleichen Sie NAMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
37.25 | 4.10B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-17 | Eingeleitet | Goldman | Neutral |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-06-10 | Eingeleitet | Stifel | Buy |
| 2025-06-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-15 | Eingeleitet | TD Cowen | Buy |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
NewAmsterdam Pharma Company N.V. $NAMS Holdings Lifted by Maverick Capital Ltd. - MarketBeat
Price-Driven Insight from (NAMS) for Rule-Based Strategy - news.stocktradersdaily.com
It is Poised to be a Bull Market for NewAmsterdam Pharma Company NV (NAMS) - setenews.com
SCYNEXIS (NASDAQ:SCYX) versus NewAmsterdam Pharma (NASDAQ:NAMS) Head to Head Analysis - Defense World
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Affinity Asset Advisors LLC - Defense World
NewAmsterdam Pharma’s REMBRANDT Trial: A Potential Game-Changer in Cardiovascular Treatment - MSN
NewAmsterdam Pharma Co (NAMS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
NAMS Analyst Forecasts - Quiver Quantitative
NewAmsterdam Pharma Company Grants Inducement Share Options to New Hires - Quiver Quantitative
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Saturn V Capital Management LP Buys 104,342 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock gain from lower inflationMarket Growth Review & Free Technical Pattern Based Buy Signals - Newser
Is NewAmsterdam Pharma Company N.V. (KH6) stock attractive post correction2025 Volatility Report & Weekly High Conviction Trade Ideas - Newser
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock see PE expansionJuly 2025 Macro Moves & Entry and Exit Point Strategies - Newser
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownHere's Why - MarketBeat
NAMS: PREVAIL CVOT remains on track for 2026, with regulatory and commercial momentum building - TradingView
JPMorgan Chase & Co. Increases Stock Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
How NewAmsterdam Pharma Company N.V. (KH6) stock trades after earningsWeekly Trade Analysis & Consistent Profit Trade Alerts - Newser
Transcript : NewAmsterdam Pharma Company N.V. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 03 - marketscreener.com
A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - setenews.com
Goldman Sachs Maintains NewAmsterdam Pharma Company N.V. (NAMS) Neutral Recommendation - MSN
Is NewAmsterdam Pharma Company N.V. (KH6) stock a defensive play amid uncertaintyEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
Will NewAmsterdam Pharma Company N.V. stock benefit from commodity pricesGap Down & Smart Money Movement Alerts - Newser
Owner Bain Capital Life Sciences Fund II LP Files To Sell 267,429 Of NewAmsterdam Pharma Co NV [NAMS] - TradingView
Owner BCLS II Investco LP Files To Sell 4,500,000 Of NewAmsterdam Pharma Co NV [NAMS] - TradingView
Will NewAmsterdam Pharma Company N.V. (KH6) stock announce special dividendWeekly Earnings Recap & Technical Entry and Exit Alerts - Newser
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a dividend growth opportunity2025 Risk Factors & AI Forecasted Entry and Exit Points - Newser
Why NewAmsterdam Pharma Company N.V. (KH6) stock signals breakout potential2025 Stock Rankings & Low Drawdown Momentum Ideas - Newser
Franklin Resources Inc. Purchases 78,300 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
(NAMS) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock outperform in 2025 bull marketPortfolio Gains Report & Technical Buy Zone Confirmation - BỘ NỘI VỤ
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December - Sahm
NewAmsterdam Pharma (NASDAQ:NAMS) Sets New 12-Month HighHere's Why - MarketBeat
NewAmsterdam Pharma stock hits all-time high at 41.56 USD - Investing.com India
NewAmsterdam Pharma stock hits all-time high at 41.56 USD By Investing.com - Investing.com Australia
Discipline and Rules-Based Execution in NAMSW Response - news.stocktradersdaily.com
What drives NewAmsterdam Pharma Company NV KH6 stock priceDebt-to-Equity Ratio Analysis & Get Ahead with Our Profit-Packed Picks - earlytimes.in
Bank of New York Mellon Corp Acquires New Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Is NewAmsterdam Pharma Company N.V. Equity Warrant stock a top pick in earnings seasonSwing Trade & Safe Investment Capital Preservation Plans - newser.com
Can a trend reversal in NewAmsterdam Pharma Company N.V. Equity Warrant lead to recovery - newser.com
Technical analysis overview for NewAmsterdam Pharma Company N.V. Equity Warrant stockMarket Movers & Risk Controlled Stock Alerts - newser.com
Is NewAmsterdam Pharma Company N.V. stock a good choice for value investorsQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Will NewAmsterdam Pharma Company N.V. stock maintain dividend yield - newser.com
Is NewAmsterdam Pharma Company N.V. (KH6) stock a fit for income portfoliosOil Prices & Long-Term Growth Stock Strategies - newser.com
How NewAmsterdam Pharma Company N.V. stock performs in high volatility marketsPortfolio Gains Report & Safe Entry Zone Identification - newser.com
What does recent volatility data suggest for NewAmsterdam Pharma Company N.V. Equity WarrantPortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
How NewAmsterdam Pharma Company N.V. (KH6) stock compares with tech leaders2025 Momentum Check & Risk Adjusted Swing Trade Ideas - newser.com
Visual analytics tools that track NewAmsterdam Pharma Company N.V. Equity Warrant performanceIndex Update & Weekly High Momentum Picks - newser.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs in stagflation2025 Biggest Moves & AI Forecast for Swing Trade Picks - newser.com
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock recover faster than marketJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
(NAMS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):